Pharma’s Take On The Pelosi Drug-Pricing Bill: Fair Warning Or Fearmongering?
The pharmaceutical industry’s argument that capping drug prices would compromise drug innovation stands “on very shaky ground.â€
Drug Costs
301 - 320 of 698 Results
-
-
HHS Hands Out Free HIV Prevention Drugs. Do You Qualify?
Called “Ready, Set, PrEP,†the federal program will provide medication that can reduce the chances of getting AIDS to at-risk patients who don’t have insurance.
-
KHN’s ‘What The Health?’: How’s That Open Enrollment Going?
Open enrollment for the Affordable Care Act’s marketplace plans is halfway over and, so far, the number of people signing up is down, but not dramatically. Meanwhile, Congress and President Donald Trump can’t seem to agree on what to do about teen vaping, drug prices or “surprise†medical bills. And Democrats lurch to the left on abortion. Paige Winfield Cunningham of The Washington Post, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news.
-
White House Unveils Finalized Health Care Price Transparency Rule
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
-
KHN’s ‘What The Health’: Spending Bill Slowdown
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.â€
-
Voters Say Congress Needs To Curb Drug Prices, But Are Lawmakers Listening?
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
Listen: HHS Files Challenge Over Rights To Gilead’s HIV-Prevention Drug
KHN's Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
-
Analysis: Elizabeth Warren Throws Down The Gauntlet
She has led the way, but all the candidates need to come clean about their health care proposals.
-
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns
The agency approved Gilead’s “game changer†hepatitis C cure, bypassing concerns raised by its own federal inspectors.
-
Moved Overseas For School, Stayed For Insulin
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
-
Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
KHN’s ‘What The Health?’: Democrats Do Drugs (Prices)
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,†the panelists recommend their favorite health stories of the week.
-
California Governor’s Bill-Signing Marathon Offers Glimpse Of 2020 Issues
California Gov. Gavin Newsom signed off on an array of health care bills that will significantly affect the lives of Californians, including many college students, pregnant women, schoolchildren and dialysis patients.
-
California’s New Transparency Law Reveals Steep Rise In Wholesale Drug Prices
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
As Medicare Enrollment Nears, Popular Price Comparison Tool Is Missing
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.
By Susan Jaffe -
KHN’s ‘What The Health?’: Impeachment And The Health Agenda
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
As Off-Label Use Spreads, Supplies Of Niche Drugs And Patients’ Patience Grow Short
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.